PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
August 1, 1992Circulation Research226 citationsOpen Access

Mechanism of flecainide's antiarrhythmic action in experimental atrial fibrillation.

View Full Paper
ZWZhiguo WangPPPierre PagéSNStanley Nattel

Key Result

Flecainide terminated atrial fibrillation in 100% of experimental dogs compared to 0% with glucose placebo (p<0.0001) by causing tachycardia-dependent increases in atrial effective refractory period.

Study Design

Type

RCT (n=16)

Blinding

Blinded

Randomization

Randomized order

Structured PICO

Does flecainide terminate atrial fibrillation in an experimental dog model?

P
Population
16 dogs with an experimental model of sustained atrial fibrillation produced by a brief burst of atrial pacing in the presence of vagal stimulation
I
Intervention
Flecainide at two dose levels
C
Comparator
Isotonic glucose placebo
O
Outcome
Termination of atrial fibrillationsurrogate

Flecainide terminates experimental atrial fibrillation by causing tachycardia-dependent increases in atrial effective refractory period, increasing the wavelength to a point where reentry cannot be sustained.

Main Result

Absolute Event Rate: 100% vs 0%

p-value: p=<0.0001

Abstract

Class Ic antiarrhythmic drugs are effective in the treatment of atrial fibrillation, but their mechanism of action is unknown. In previous work, we have found that flecainide causes tachycardia-dependent increases in atrial action potential duration (APD) and effective refractory period (ERP) by reducing APD accommodation to heart rate. The present study was designed to evaluate the efficacy and mechanisms of action of flecainide in an experimental model of sustained atrial fibrillation (AF). AF was produced by a brief burst of atrial pacing in the presence of vagal stimulation and persisted spontaneously until vagal stimulation was stopped. The actions of flecainide at two dose levels were compared with those of isotonic glucose placebo in each dog, with a randomized order of blinded drug administration. Flecainide terminated AF in all 16 dogs, while glucose was effective in none (p less than 0.0001). Flecainide increased atrial ERP and reduced conduction velocity in a tachycardia-dependent manner. Doses of flecainide that converted AF resulted in larger changes in ERP than in conduction velocity, increasing the minimum path-length capable of supporting reentry (wavelength). In addition, flecainide reduced regional heterogeneity in ERP and wavelength, an action opposite that of vagal stimulation. Atrial epicardial mapping with a 112-electrode atrial array was used to study the mechanism of flecainide action on AF. Under control conditions, multiple small zones of reentry coexisted. Flecainide progressively increased the size of reentry circuits, decreased their number, and slowed the frequency of atrial activation until the arrhythmia finally terminated; all changes were compatible with an increase in wavelength. We conclude that flecainide terminates atrial fibrillation in this experimental model by causing tachycardia-dependent increases in atrial ERP, which increase the wavelength at the rapid rates characteristic of AF to the point that the arrhythmia can no longer sustain itself.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Wang et al. (1992) conducted an RCT in Sustained atrial fibrillation (n=16). Flecainide vs. Isotonic glucose placebo was evaluated on Termination of atrial fibrillation (p=<0.0001). Flecainide terminated atrial fibrillation in 100% of experimental dogs compared to 0% with glucose placebo (p<0.0001) by causing tachycardia-dependent increases in atrial effective refractory period.

synapsesocial.com/papers/6a0919dff318adf1ecb61732https://doi.org/10.1161/01.res.71.2.271
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Evaluation of flecainide acetate in rapid atrial fibrillation complicating wolff‐parkinson‐white syndrome1985 · 43 citations
  2. 2Acute conversion of atrial fibrillation to sinus rhythm: clinical efficacy of flecainide acetate. Comparison of two regimens1988 · 157 citations
  3. 3Transitions among atrial fibrillation, atrial flutter, and sinus rhythm during procainamide infusion and vagal stimulation in dogs with sterile pericarditis1991 · 31 citations
  4. 4Mode of Action of a New Class IC Drug (ORG 7797) Against Atrial Fibrillation in Conscious Doges1991 · 50 citations
  5. 5Effects of N-Acetylprocainamide and Recainam in the Pharmacologic Conversion and Suppression of Experimental Canine Atrial Flutter1988 · 19 citations